Combined oestrogen and progestin has equivocal effect on gynaecological cancers - 24/08/11
Abstract |
Question |
Does oestrogen plus progestin affect the rate of gynaecologic cancers in healthy post-menopausal women?
Study design |
Double blind randomised controlled trial.
Main results |
There were no significant differences in the incidence of ovarian or endometrial cancers between groups (see Table 1). The distribution of class and grade of disease and its severity at diagnosis did not differ between groups. More women in the hormone group required unplanned biopsies (33% vs. 6%, p<0.001), with a greater proportion of successful biopsies revealing normal results (85% vs 68%, p<0.001).
| ||||||||||||||||||||||||
Authors’ conclusions |
Rates of ovarian and endometrial cancers were low in both groups, suggesting that these results need not unduly influence women when considering treatment for menopausal symptoms. Combined oestrogen plus progestin may slightly alter the risk of ovarian and endometrial cancer, and needs confirmation.
Le texte complet de cet article est disponible en PDF.Keywords : Oestrogen replacement therapy, Gynaecological cancers, Incidence, Post-menopausal women, Randomised controlled trial
Plan
 | Abstracted from: Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739–1748. |
Vol 8 - N° 2
P. 99-101 - avril 2004 Retour au numéro
Article précédent
- The whispered voice test detects hearing impairment in adults and children, but needs to be standardised
- Diane L Sabo
- Oestrogen plus progestin significantly improves bone mineral density and reduces risk of fracture
- Birgitta Tengstrand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?